Back to search results

TRIAL Web-Based Application for Acute Leukemia

This study is testing a web-based application called TRIAL (Tools for Reducing Inequity in Acute Leukemia). This application aims to help people with acute leukemia by providing information about their disease and clinical trials, as well as access to resources from the Leukemia and Lymphoma Society (LLS). You would be given an iPad for 14 days to use the application. Researchers want to see how many people complete a post-test and how easy the application is to use. This study is for adults aged 18 or older who speak English, have acute leukemia, and are admitted to a DFCI-affiliated hospital unit. The study is currently unclear on its recruitment status.

Study design
This is a single-arm study, meaning all participants will receive the same intervention. About 75 people are expected to participate.
What's involved
You would participate in screening for eligibility and complete questionnaires. Your participation is expected to last about 14 weeks.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes at Day 14 or date of discharge, and again at approximately 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06907797

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Recruiting
NAAges 18+InterventionalHealth services
Dana-Farber Cancer Institute
~75 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:TRIAL Web-Based Application

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Post-Test Completion Rate
Measured over Day 14 or date of discharge
+2 more outcomes measured

Conditions

Acute Leukemia
Leukemia

Explore related trials

Acute Leukemia

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Andrew Hantel, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Andrew Hantel, MD
[email protected]
617-582-9394
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 or older
English speaking
Ability to understand and willingness to sign written informed consent
Clinical suspicion of acute leukemia
Admitted to DFCI-affiliated inpatient unit

Exclusion

Cognitive impairment rendering the individual unable to participate in beta testing
This will be assessed by focused chart review and consultation with the patients' inpatient care team.
The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
Inability to participate in in-person application testing.
Patients who participated in alpha-testing through protocol 23-404 (Appendix A)

What this trial measures

  • Post-Test Completion RateDay 14 or date of discharge

    Defined as the proportion of completed post-tests compared to the overall total of 75. Retention feasibility is defined as ≥ 70% of post-test completions, or 53 completions.

  • System Usability Scale (SUS) ScoreDay 14 or date of discharge

    Assessed by the System Usability Scale (SUS), a 10-item measure rated on a 5-point Likert scale from 1 "Strongly Disagree" to 5 "Strongly Agree" with a total scores range of 0 to 100. A higher score represents greater usability.

  • Percentage of Participants Scoring ≥68 on SUSapproximately 12 months (based on total accrual duration)

    Defined as the proportion of participants who score ≥68 on the SUS compared to the overall enrollment of 75 participants. Usability of the intervention is defined as \>70%, or 53 participants.